Margaret S. Lee
Nessuna posizione attualmente
Profilo
Margaret S.
Lee worked as VP-Research & Translational Development at Karyopharm Therapeutics, Inc. and as Vice President-Research & Translational Medicine at Zalicus, Inc. She holds a doctorate degree from Sackler School of Graduate Biomedical Sciences.
Precedenti posizioni note di Margaret S. Lee
| Società | Posizione | Fine |
|---|---|---|
Zalicus, Inc.
 Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Direttore Tecnico/Scientifico/R&S | - |
| KARYOPHARM THERAPEUTICS INC. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Margaret S. Lee
| Sackler School of Graduate Biomedical Sciences | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Zalicus, Inc.
Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Margaret S. Lee
